Muscle Protein Synthesis After Whole Egg vs. Egg White Consumption
The Consumption of Whole Eggs Versus Egg Whites to Stimulate Postprandial Muscle Protein Synthesis
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
On both infusion trials, participants will report to the laboratory at 0700 h after an overnight fast. Upon arrival to the lab, a baseline breath sample will be collected for determination of 13CO2 enrichment by isotope ratio mass spectrometry. A Teflon catheter will be inserted into an antecubital vein for baseline blood sample collection (t=-210 min) and then participants will receive priming doses of NaH13CO2 (2.35 µmol·kg-1), L-[1-13C]leucine (7.6 µmol·kg-1), and L-[ring-2H5]phenylalanine (2.0 µmol·kg-1). Subsequently, a continuous intravenous infusion of L-[1-13C]leucine (0.10 µmol·kg-1·min-1) and L-[ring-2H5]phenylalanine (0.05 µmol·kg-1·min-1) will be initiated (t=-210 min) and maintained over the infusion trials. A second Teflon catheter willinserted into a heated dorsal hand vein for repeated arterialized blood sampling and remained patent by a 0.9% saline drip. Breath samples and arterialized blood samples and will be collected every 30 or 60 min during the postabsorptive- and postprandial states. In the post-absorptive state of infusion trial 1, muscle biopsies will be collected at t=-150 and -30 min of infusion to determine basal-state myofibrillar protein synthesis rates, relative skeletal muscle amino acid transporter content, and anabolic-related signaling. In the subsequent cross-over trial only 1 muscle biopsy will be collected at t=-30 for Western blot analysis and postabsorptive myofibrillar protein-bound tracer enrichment. After collection of the resting muscle biopsy at t=-30 for both trials, the participants will perform resistance exercise that consists of 4 sets of 10 repetitions at 80% of 10-RM for both leg press and leg extension exercise.
Immediately after completion of the exercise bout, participants will consume 3 whole eggs or an equivalent amount of protein from egg whites (t=0 min). Completion of the meal will mark the start of the postprandial phase (t=0 min) and additional muscle biopsies will be collected at t=120 and 300 min.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Illinois
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Freer Hall
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male
- Aged 18-35 years
- Healthy, active (self-reported to exercise 2 - 4 times per week)
- BMI > 18.5 and < 25 kg/m2
Exclusion Criteria:
- Smoking
- Known allergies to egg consumption
- Vegans
- Diagnosed GI tract diseases
- Arthritic conditions
- A history of neuromuscular problems
- Diagnosed cognitive impairments
- Recent (1 year) participation in amino acid tracer studies
- Predisposition to hypertrophic scarring or keloid formation
- Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
- High blood pressure (Systolic > 140 mm HG; Diastolic > 90 mm HG)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Whole eggs
After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
|
Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
Participants will ingestion whole eggs immediately after resistance exercise
|
|
Experimental: Egg Whites
After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
|
Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
Participants will ingestion whole eggs immediately after resistance exercise
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fractional synthetic rate of myofibrillar proteins to whole egg and egg white ingestion
Zeitfenster: Postabsorptive for 3 hours, Postprandial for 5 hours
|
Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 5 hr after the ingestion of the experimental beverages.
This will allow us to assess the change from the postabsorptive to the postprandial period
|
Postabsorptive for 3 hours, Postprandial for 5 hours
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phosphorylation of muscle anabolic signaling
Zeitfenster: Baseline and at 2 and 5 hours after protein ingestion
|
Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 5 hr after the ingestion of the whole egg and egg whites
|
Baseline and at 2 and 5 hours after protein ingestion
|
|
Exogenous rate of leucine appearance after ingestion of whole eggs and egg whites.
Zeitfenster: 5 hour postprandial phase
|
Dietary derived leucine availability will be measured during the 5 h postprandial phase to compare the dietary-derived leucine availability after whole egg and egg white ingestion.
|
5 hour postprandial phase
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Nicholas A Burd, Ph.D., Assistant Professor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 15693
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .